end sight pt
post strong us impella grow ou
handili beat forecast impella remain less penetr
current indic potenti new indic could expand us
opportun intern adopt even lower grow bodi
clinic data establish support reimburs competit
add cleanest growth stori med-tech pt
realli realli good post top-line beat
driven shock pci growth us impella revenu grew protect
pci shock achiev ou sale y/i
driven strength germani higher util adopt
high risk pci progress japan exceed abmd goal rp ad new site
grew revenu gross margin came bp forecast
geograph mix invest manufactur capabl guid
sale growth season weaker uptick
oper margin revenu model settl
penetr lot momentum impella
target hospit site penetr impella rp
site penetr impella rp earlier product cycl
product opportun expand site reach importantli drive
use increas number surgeon use impella frequenc use
penetr previous state patient address market us
grow accept impella standard care particularli shock
continu market develop effort includ tv campaign case
use impella get harder make
rais pt remain cleanest growth stori med-tech core
shock pci market still grossli under-penetrated well establish clinic rational
use support reimburs econom expand pipelin ecp btr new
indic stemi new geograph market germani japan littl competit
clear runway continu outsiz perform
pt repres sale high-end med-tech risk
includ competit adopt underli market growth
estim reflect account
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
ww impella growth sustain
reach sale
us market penetr
gradual penetr japan
best-in-class growth profil med-tech
impella target market less
penetr current market
geographi technolog pipelin
support secur reimburs fast-track
estim factor contribut stemi patient
multipl sale price
competitor sight next year
ww impella growth lead sale excess
uptak impella adopt
commerci launch japan faster expect
acceler roll-out germani
upsid stemi patient opportun begin
take-out larger strateg
target multipl higher sale yield target
price
ww impella growth slow lower adopt
limit penetr japan
slow roll-out germani
adopt impella rp
usag us reimburs code
stemi studi fail show benefit impella
competit enter short-run
price
page
pleas see import disclosur inform page report
